Security
OnKure Therapeutics, Inc. Class A Common Stock · OKUR
OKURNASDAQCommon stockCurrentCIK 1637715Updated Oct 8, 2026
Name history
Reneo Pharmaceuticals, Inc. · through Oct 2, 2024
OKUR price & chart
Loading TradingView…
NASDAQ:OKUR on TradingView ↗About the company
OnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of vascular anomalies and cancers that are underserved by available therapies. Using a structure and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of vascular anomalies and cancer. OnKure aims to become a leader in targeting PI3Kα and has multiple programs designed to enable best-in-class targeting of this important molecular target.
In the news
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 ↗
Recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
4 filing
4 filing
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 72,835,000Source | 77,645,000Source | 179,353,000Source | 86,070,000Source | 78,717,000Source | 198,694,000Source | 99,882,000Source | 84,639,000Source | 62,117,000Source | 114,907,000Source | 107,436,000Source | 108,182,000Source |
| Property, Plant and Equipment, NetUSD | 720,000Source | 59,000Source | 435,000Source | 821,000Source | 81,000Source | 519,000Source | 925,000Source | 102,000Source | 618,000Source | 1,025,000Source | 134,000Source | 453,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 70,331,000Source | 60,689,000Source | 166,502,000Source | 83,374,000Source | 35,970,000Source | 192,106,000Source | 96,661,000Source | 20,375,000Source | 59,050,000Source | 110,761,000Source | 27,632,000Source | 19,927,000Source |
| Assets, CurrentUSD | 71,526,000Source | 76,999,000Source | 177,677,000Source | 84,552,000Source | 77,990,000Source | 197,482,000Source | 98,172,000Source | 83,927,000Source | 60,839,000Source | 113,003,000Source | 106,622,000Source | 106,353,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,195,000Source | 331,000Source | 1,291,000Source | 1,178,000Source | 1,316,000Source | 5,376,000Source | 1,511,000Source | 1,092,000Source | 1,789,000Source | 2,242,000Source | 3,659,000Source | 5,180,000Source |
| Operating Lease, Right-of-Use AssetUSD | 485,000Source | 440,000Source | 840,000Source | 581,000Source | 493,000Source | 288,000Source | 676,000Source | 546,000Source | 387,000Source | 770,000Source | 599,000Source | 1,292,000Source |
| Other Assets, NoncurrentUSD | 104,000Source | 147,000Source | 401,000Source | 116,000Source | 153,000Source | 405,000Source | 109,000Source | 64,000Source | 273,000Source | 109,000Source | 81,000Source | 84,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 6,407,000Source | 3,627,000Source | 7,245,000Source | 7,904,000Source | 1,848,000Source | 14,341,000Source | 9,234,000Source | 3,397,000Source | 5,933,000Source | 11,079,000Source | 18,826,000Source | 8,212,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Common Stock, Value, IssuedUSD | — | 0Source | — | — | 3,000Source | — | — | 3,000Source | — | — | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 267,165,000Source | 309,969,000Source | 416,861,000Source | 264,204,000Source | 309,140,000Source | 413,747,000Source | 261,296,000Source | 308,151,000Source | 270,424,000Source | 258,551,000Source | 307,073,000Source | 236,693,000Source |
| Retained Earnings (Accumulated Deficit)USD | -200,738,000Source | -235,953,000Source | -244,744,000Source | -186,039,000Source | -232,261,000Source | -229,398,000Source | -170,649,000Source | -226,900,000Source | -214,241,000Source | -154,724,000Source | -218,474,000Source | -136,683,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 2,000Source | -13,000Source | — | -13,000Source | — | — | -12,000Source | — | — | 8,000Source | -43,000Source |
| Stockholders' Equity Attributable to ParentUSD | 66,428,000Source | -135,050,000Source | 172,108,000Source | 78,166,000Source | -123,577,000Source | 184,353,000Source | 90,648,000Source | -111,261,000Source | 56,184,000Source | 103,828,000Source | 88,610,000Source | 99,970,000Source |
| Liabilities and EquityUSD | 72,835,000Source | 77,645,000Source | 179,353,000Source | 86,070,000Source | 78,717,000Source | 198,694,000Source | 99,882,000Source | 84,639,000Source | 62,117,000Source | 114,907,000Source | 107,436,000Source | 108,182,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,247,000Source | 3,248,000Source | 6,643,000Source | 7,597,000Source | 1,348,000Source | 14,329,000Source | 8,785,000Source | 2,814,000Source | 5,921,000Source | 10,530,000Source | 18,177,000Source | 7,124,000Source |
| Operating Lease, Liability, CurrentUSD | 567,000Source | 286,000Source | 336,000Source | 556,000Source | 331,000Source | 409,000Source | 546,000Source | 331,000Source | 549,000Source | 536,000Source | 331,000Source | 404,000Source |
| Accounts Payable, CurrentUSD | 1,290,000Source | 237,000Source | 1,999,000Source | 2,381,000Source | 64,000Source | 11,022,000Source | 2,344,000Source | 676,000Source | 1,433,000Source | 2,968,000Source | 8,717,000Source | 1,893,000Source |
| Operating Lease, Liability, NoncurrentUSD | 120,000Source | 379,000Source | 590,000Source | 267,000Source | 492,000Source | 0Source | 409,000Source | 576,000Source | — | 549,000Source | 642,000Source | 1,059,000Source |
| Other Liabilities, NoncurrentUSD | 40,000Source | — | 12,000Source | 40,000Source | — | 12,000Source | 40,000Source | — | 12,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 725,000Source | — | 4,660,000Source | 953,000Source | — | 5,895,000Source | 1,807,000Source | — | 7,026,000Source | 9,129,000Source | 4,827,000Source |
| Short-term InvestmentsUSD | — | 15,979,000Source | — | — | 40,704,000Source | — | — | 62,460,000Source | — | — | 75,331,000Source | 81,246,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | —Source | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 108,000Source | 114,000Source | — | — | 104,000Source | 118,000Source | 447,000Source | 459,000Source | 170,000Source | 88,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,780,000Source | 2,745,000Source | 11,633,000Source | 4,530,000Source | 5,112,000Source | 4,320,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,938,000Source | -14,005,000Source | -51,828,000Source | -51,117,000Source | -63,682,000Source | -47,362,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -5,000Source | -18,000Source | -46,000Source | 15,873,000Source | 10,522,000Source | -57,842,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,000Source | 18,000Source | 46,000Source | 52,000Source | 221,000Source | 346,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 4,403,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 145,999,000Source | -77,000Source | 163,000Source | 116,129,000Source | 60,865,000Source | 471,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 133,056,000Source | -14,100,000Source | -51,711,000Source | 80,885,000Source | 7,705,000Source | -104,733,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 70,331,000Source | 7,959,000Source | 166,502,000Source | 83,374,000Source | 192,106,000Source | 96,661,000Source | 59,050,000Source | 110,761,000Source | 27,632,000Source | 19,927,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,961,000Source | 77,000Source | 3,049,000Source | 2,908,000Source | 2,780,000Source | 2,745,000Source | 11,633,000Source | 4,530,000Source | 5,112,000Source | 4,320,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | 142,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | 0Source | — | — | — | — | -54,000Source | -54,000Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -54,000Source | — | -17,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -6,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,586,000Source | 1,396,000Source | 4,288,000Source | 3,711,000Source | 3,908,000Source | 3,988,000Source | 14,690,000Source | 10,591,000Source | 26,440,000Source | 16,143,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,699,000Source | -11,556,000Source | -15,346,000Source | -15,390,000Source | -15,157,000Source | -15,925,000Source | -59,517,000Source | -52,673,000Source | -77,388,000Source | -51,955,000Source |
| Operating ExpensesUSD | — | — | 15,501,000Source | 11,512,000Source | 16,899,000Source | 16,324,000Source | 15,615,000Source | 17,000,000Source | 62,950,000Source | 54,386,000Source | 83,053,000Source | 53,848,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 400,000Source | 500,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 300,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | 972,000Source | — | — | — | — | — | — | 5,665,000Source | 1,893,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 193,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | 15,900,000Source | 15,900,000Source | 242,000,000Source | 44,100,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | —Source | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Operating Income (Loss)USD | — | — | -15,501,000Source | -11,512,000Source | -16,899,000Source | -16,324,000Source | -15,615,000Source | -17,000,000Source | -62,950,000Source | -54,386,000Source | -83,053,000Source | -53,848,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 972,000Source | — | — | — | — | — | — | 5,665,000Source | 1,893,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -77,388,000Source | -51,955,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -14,699,000Source | -11,556,000Source | -15,346,000Source | -15,390,000Source | -15,157,000Source | -15,925,000Source | -59,517,000Source | -52,673,000Source | -77,388,000Source | -51,955,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.09Source | -36.55Source | -0.31Source | -1.14Source | -1.11Source | -1.19Source | -4.4Source | -15.28Source | -2.52Source | -2.12Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.09Source | -36.55Source | -0.31Source | -1.14Source | -1.11Source | -1.19Source | -4.4Source | -15.28Source | -2.52Source | -2.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 13,530,892Source | 316,142Source | 49,869,177Source | 13,509,080Source | 13,674,577Source | 13,424,335Source | 13,515,915Source | 3,447,071Source | 30,676,455Source | 24,496,425Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 13,530,892Source | 316,142Source | 49,869,177Source | 13,509,080Source | 13,674,577Source | 13,424,335Source | 13,515,915Source | 3,447,071Source | 30,676,455Source | 24,496,425Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,586,000Source | 1,396,000Source | 4,288,000Source | 3,711,000Source | 3,908,000Source | 3,988,000Source | 14,690,000Source | 10,591,000Source | 26,440,000Source | 16,143,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | — | — | -78,132,000Source | -51,994,000Source |
| Interest Income (Expense), NetUSD | — | — | 802,000Source | -44,000Source | 1,553,000Source | 934,000Source | 458,000Source | 1,075,000Source | 3,433,000Source | 1,713,000Source | — | — |
| Interest Income, OperatingUSD | — | — | 804,000Source | 174,000Source | 1,553,000Source | 934,000Source | 458,000Source | 1,075,000Source | 3,441,000Source | 2,013,000Source | — | — |
| Operating ExpensesUSD | — | — | 15,501,000Source | 11,512,000Source | 16,899,000Source | 16,324,000Source | 15,615,000Source | 17,000,000Source | 62,950,000Source | 54,386,000Source | 83,053,000Source | 53,848,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 400,000Source | 500,000Source |
| Research and Development ExpenseUSD | — | — | 11,915,000Source | 10,116,000Source | 12,611,000Source | 12,613,000Source | 11,707,000Source | 13,012,000Source | 48,260,000Source | 43,795,000Source | 56,613,000Source | 37,705,000Source |
Offerings
Registration 333-295304
Filing attachments
okur-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 okur-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights -- Executing IND-enabling activities for next-generation PI3Ka pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Hosted a Key Opinion Leader event highlighting the evolving PI3Kα treatment landscape and the scientific rationale supporting OnKure's next…
Read attachment ↗okur-ex4_5.htm · S-8 · 2026-06-05
Exhibit 4.5 ONKURE THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, each capitalized term used in this Restricted Stock Unit Agreement, which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, and all other exhibits, appendices, and addenda attached hereto (the “Award Agreement”), w…
Read attachment ↗okur-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 okur-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 OnKure Therapeutics Reports First Quarter 2026 Financial Results -- Announced nomination of OKI-355, a next-generation PI3Ka pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company’s pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Ka pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private…
Read attachment ↗d910791dex41.htm · 8-K · 2026-03-30
EX-4.1 2 d910791dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗